CervoMed (NASDAQ: CRVO) has announced that it has completed enrollment in the Phase 2a study to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in patients with nonfluent/agrammatic variant of primary progressive aphasia (nfvPPA)—a type of frontotemporal dementia (FTD).
According to CervoMed, interim biomarker data from the study will be presented at the 19th CTAD Conference in Boston, Massachusetts, taking place November 16–19, 2026.
In a statement, Dr. John A. Alam, CEO of CervoMed, commented, “The rapid enrollment of this trial reflects the belief of the FTD academic medical community in the potential of neflamapimod to address this disease and the critical need for treatments for nfvPPA. Recently published preclinical data help elucidate the mechanisms behind FTD that are driven by tau pathology and demonstrate the potential of neflamapimod to reverse the neuronal deficits associated with forms of tau-related FTD, such as nfvPPA, via the inhibition of p38α. We look forward to sharing the first biomarker data with neflamapimod in patients with nfvPPA early in the fourth quarter of 2026 and the first clinical data in the first quarter of 2027.”
